Previous 10 | Next 10 |
MONT-SAINT-GUIBERT, Belgium, May 29, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that management plans to attend the following events in ...
MONT-SAINT-GUIBERT, Belgium, May 16, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the selection of three abstracts for poster presentation at th...
MONT-SAINT-GUIBERT, Belgium, May 09, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced an update on operational developments for the first quarter en...
MONT-SAINT-GUIBERT, Belgium, May 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that management plans to attend the following events in ...
MONT-SAINT-GUIBERT, Belgium, April 17, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that clinical data from the SHRINK and alloSHRINK Phas...
MONT-SAINT-GUIBERT, Belgium, April 01, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that management plans to present at four investor conf...
Celyad SA (CYAD) Q4 2018 Results Earnings Conference Call March 29, 2019, 08:00 AM ET Company Participants Anne Moore - Vice President Corporate Strategy Christian Homsy - Chief Executive Officer Filippo Petti - Chief Financial Officer David Gilham - Vice President, Research &a...
Celyad (NASDAQ: CYAD ): FY GAAP EPS of -€3.36. More news on: Celyad SA, Earnings news and commentary, Healthcare stocks news, Read more ...
THINK Phase 1 trial (CYAD-01 with no preconditioning) showed a complete response in 40% of patients with AML/MDS THINK CyFlu Phase 1 demonstrated CYAD-01 is well-tolerated, with no dose-limiting toxicity or treatment-related grade 3 or above adverse events (AEs) observed First data from ...
MONT-SAINT-GUIBERT, Belgium, March 28, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T therapies, today announced the appointment of Filippo Petti as Chief Executive Officer (CEO)...
News, Short Squeeze, Breakout and More Instantly...
Celyad SA Company Name:
CYAD Stock Symbol:
NASDAQ Market:
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced...
MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Bid Price No...
MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Letterȁ...